Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IFRX NYSE:PRME NASDAQ:REPL NASDAQ:ZYBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIFRXInflaRx$1.29-12.5%$1.02$0.71▼$2.82$85.05M1.43464,643 shs839,459 shsPRMEPrime Medicine$4.08-0.1%$3.86$1.11▼$5.17$549.87M2.382.55 million shs2.32 million shsREPLReplimune Group$5.72-4.9%$6.75$2.68▼$17.00$446.11M0.513.91 million shs961,440 shsZYBTZhengye Biotechnology$9.63+4.6%$7.04$3.50▼$14.30$454.21MN/A311,079 shs269,397 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIFRXInflaRx-6.96%-6.37%+76.47%+87.50%+2.08%PRMEPrime Medicine+4.88%+20.00%+17.92%+179.45%-0.24%REPLReplimune Group+0.33%+3.44%+14.48%-38.55%-42.04%ZYBTZhengye Biotechnology-11.44%+17.03%+21.83%+45.27%+920,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIFRXInflaRx$1.29-12.5%$1.02$0.71▼$2.82$85.05M1.43464,643 shs839,459 shsPRMEPrime Medicine$4.08-0.1%$3.86$1.11▼$5.17$549.87M2.382.55 million shs2.32 million shsREPLReplimune Group$5.72-4.9%$6.75$2.68▼$17.00$446.11M0.513.91 million shs961,440 shsZYBTZhengye Biotechnology$9.63+4.6%$7.04$3.50▼$14.30$454.21MN/A311,079 shs269,397 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIFRXInflaRx-6.96%-6.37%+76.47%+87.50%+2.08%PRMEPrime Medicine+4.88%+20.00%+17.92%+179.45%-0.24%REPLReplimune Group+0.33%+3.44%+14.48%-38.55%-42.04%ZYBTZhengye Biotechnology-11.44%+17.03%+21.83%+45.27%+920,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIFRXInflaRx 3.00Buy$6.20382.12% UpsidePRMEPrime Medicine 2.75Moderate Buy$8.92118.81% UpsideREPLReplimune Group 2.10Hold$6.5013.74% UpsideZYBTZhengye Biotechnology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IFRX, REPL, ZYBT, and PRME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025REPLReplimune GroupHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral9/2/2025IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.008/8/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.007/30/2025REPLReplimune GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight7/23/2025REPLReplimune GroupBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$17.00 ➝ $3.007/23/2025REPLReplimune GroupBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Underperform$27.00 ➝ $2.007/23/2025REPLReplimune GroupHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/22/2025REPLReplimune GroupLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/22/2025REPLReplimune GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/22/2025REPLReplimune GroupJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$31.00 ➝ $6.007/22/2025REPLReplimune GroupLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$21.00 ➝ $3.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIFRXInflaRx$180K479.61N/AN/A$1.13 per share1.14PRMEPrime Medicine$4.96M110.54N/AN/A$1.37 per share2.97REPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/AZYBTZhengye Biotechnology$186.36M2.44$0.10 per share100.93$1.02 per share9.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIFRXInflaRx-$49.85M-$0.80N/AN/AN/AN/A-71.76%-57.68%11/14/2025 (Estimated)PRMEPrime Medicine-$198.13M-$1.56N/AN/AN/AN/A-107.87%-74.97%N/AREPLReplimune Group-$247.30M-$3.24N/AN/AN/AN/A-69.34%-52.81%11/11/2025 (Estimated)ZYBTZhengye Biotechnology$1.55MN/A0.00∞N/AN/AN/AN/AN/ALatest IFRX, REPL, ZYBT, and PRME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025IFRXInflaRx-$0.24-$0.24N/A-$0.24$0.02 million$0.05 million8/7/2025Q1 2026REPLReplimune Group-$0.83-$0.95-$0.12-$0.95$0.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIFRXInflaRxN/AN/AN/AN/AN/APRMEPrime Medicine$1.4535.48%N/AN/A N/AREPLReplimune GroupN/AN/AN/AN/AN/AZYBTZhengye BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIFRXInflaRxN/A4.103.78PRMEPrime MedicineN/A6.506.50REPLReplimune Group0.216.946.94ZYBTZhengye Biotechnology0.011.310.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIFRXInflaRx42.39%PRMEPrime Medicine70.37%REPLReplimune Group92.53%ZYBTZhengye BiotechnologyN/AInsider OwnershipCompanyInsider OwnershipIFRXInflaRx16.30%PRMEPrime Medicine22.74%REPLReplimune Group5.20%ZYBTZhengye BiotechnologyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIFRXInflaRx6067.13 million56.19 millionOptionablePRMEPrime Medicine234134.57 million100.38 millionOptionableREPLReplimune Group21078.06 million74.00 millionOptionableZYBTZhengye Biotechnology27847.17 millionN/AN/AIFRX, REPL, ZYBT, and PRME HeadlinesRecent News About These CompaniesZhengye Biotechnology (NASDAQ:ZYBT) Shares Gap Down - Here's WhySeptember 5, 2025 | marketbeat.comZhengye Biotechnology (NASDAQ:ZYBT) Stock Price Up 19.8% - Time to Buy?September 4, 2025 | marketbeat.comZhengye Biotechnology (NASDAQ:ZYBT) Trading Up 5.3% - What's Next?August 29, 2025 | marketbeat.comZhengye Biotechnology Holding Ltd trading resumesAugust 22, 2025 | msn.comZhengye Biotechnology Holding Ltd trading halted, volatility trading pauseAugust 21, 2025 | msn.comZYBT | Zhengye Biotechnology Holding Ltd. Company Profile & Executives ...July 17, 2025 | wsj.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results | ZYBT Stock NewsJuly 3, 2025 | gurufocus.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial ResultsJuly 3, 2025 | prnewswire.comZYBT | Zhengye Biotechnology Holding Ltd. Stock Overview (U.S.: Nasdaq) - Barron'sJuly 2, 2025 | barrons.comZYBT - Zhengye Biotechnology Holding Ltd Chart - MorningstarJune 27, 2025 | morningstar.comMZhengye Biotechnology Holding LtdJune 21, 2025 | morningstar.comMZYBT Zhengye Biotechnology Holding LimitedMay 30, 2025 | seekingalpha.comZhengye Biotechnology faces NASDAQ compliance issueMay 24, 2025 | investing.comZhengye Biotechnology Holding Limited Receives NASDAQ Delinquency Letter for Non-Compliance with Listing RequirementsMay 23, 2025 | quiverquant.comQZhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-FMay 23, 2025 | globenewswire.comShould We Be Cautious About Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 6.9%?April 7, 2025 | finance.yahoo.comZhengye Biotechnology Holding Ltd.April 3, 2025 | wsj.comZhengye Biotechnology Holding Limited (ZYBT)March 27, 2025 | finance.yahoo.comZhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment OptionJanuary 14, 2025 | globenewswire.comZhengye Biotechnology Holding Limited Announces Closing of Initial Public OfferingJanuary 8, 2025 | globenewswire.comZhengye Biotechnology Holding Limited Announces Pricing of Initial Public OfferingJanuary 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025AI Glasses to Replace Smartphones? Meta Is Taking Aim at AppleBy Leo Miller | August 16, 2025IFRX, REPL, ZYBT, and PRME Company DescriptionsInflaRx NASDAQ:IFRX$1.27 -0.20 (-13.27%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Prime Medicine NYSE:PRME$4.08 -0.01 (-0.12%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Replimune Group NASDAQ:REPL$5.72 -0.29 (-4.74%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Zhengye Biotechnology NASDAQ:ZYBT$9.63 +0.42 (+4.56%) As of 03:32 PM EasternZhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
